NeuroMetrix Initiates Patient-Focused Program for Early Detection of Diabetic Peripheral Neuropathy by Podiatrists

  NeuroMetrix Initiates Patient-Focused Program for Early Detection of
  Diabetic Peripheral Neuropathy by Podiatrists

Business Wire

WALTHAM, Mass. -- April 1, 2014

NeuroMetrix, Inc. (the “Company”) (Nasdaq: NURO), an innovative health care
company that develops wearable medical technology and point-of-care
diagnostics that helps patients and physicians better manage chronic pain,
nerve disorders, and associated sleep disturbances, today announced an
initiative to improve the detection and awareness of diabetic peripheral
neuropathy, or DPN, at a reasonable cost to patients. The program is targeted
at podiatric physicians and offers creative commercial terms to incorporate a
DPN screening program into their clinical practice with NC-stat^® DPNCheck^®
technology. This objective test will allow them to more accurately assess
their patients with diabetes for DPN and enhance the podiatric care they
provide.

NC-stat DPNCheck addresses an unmet medical need for accurate and
cost-effective screening, diagnosing and monitoring of DPN. This complication
of diabetes affects over 50% of diabetics and leads to foot ulcers and limb
amputation, as well as severe pain and an overall reduction in patient quality
of life. NC-stat DPNCheck has found growing acceptance among larger Medicare
Advantage plans where the test is used in the clinically and financially
important risk adjustment process.

U.S. podiatrists number approximately 15,000. Their central role in managing
DPN and its complications positions them to advise patients on the benefits of
early DPN detection in guiding treatment. Recent studies have not only
confirmed the benefits to patients of podiatric care but also the significant
savings in health care costs due to lower risks of hospitalization and
amputation where podiatrists are involved in the care of patients with
diabetes. Screening with NC-stat DPNCheck will help podiatrists identify
patients likely to benefit from intensive podiatric care.

“NC-stat DPNCheck is well suited to the podiatrist with a significant diabetes
practice,” said Shai N. Gozani, M.D., Ph.D., President and Chief Executive
Officer of NeuroMetrix. “Patients will benefit from awareness and treatment
that more accurately takes into account their condition. Podiatrists will find
that DPN screening can be efficiently adopted in their medical practice to
improve patient risk assessment while contributing to practice economics.”

About NeuroMetrix

NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care diagnostics that help patients and
physicians better manage chronic pain, nerve disorders, and associated sleep
disturbances. The Company has a major focus on diabetic neuropathies, which
affect over 50% of people with diabetes. If left untreated, diabetic
neuropathies trigger foot ulcers that may require amputation and cause
disabling chronic pain. The annual cost of diabetic neuropathies has been
estimated at $14 billion in the United States. The company markets the SENSUS™
Pain Management System for treating chronic pain, focusing on physicians
managing patients with painful diabetic neuropathy and other forms of chronic
pain such as fibromyalgia, post herpetic neuropathy (shingles), and conditions
with both chronic pain and disturbed sleep such as restless leg syndrome. The
company also markets the DPNCheck^® device, which is a rapid, accurate, and
quantitative point-of-care test for peripheral neuropathies such as diabetic
neuropathy. This product is used to detect neuropathies at an early stage and
to guide treatment. For more information, please visit
http://www.NeuroMetrix.com.

Contact:

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
 
Press spacebar to pause and continue. Press esc to stop.